You are here

Article Text

Article menu
Download PDFPDF
Editorial
Her2 low (but not negative): the newest biomarker on the block for gastro-oesophageal adenocarcinoma

https://doi.org/10.1136/jcp-2023-209088

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Handling editor Vikram Deshpande.

    • Twitter @jackiehechtman

    • Contributors JFH created the content and wrote this editorial.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests JFH is a full-time employee of Caris Life Sciences.

    • Provenance and peer review Commissioned; externally peer reviewed.

    Linked Articles

    • Original research
      HER2-low in gastro-oesophageal adenocarcinoma: a real-world pathological perspective
      Valentina Angerilli Paola Parente Michela Campora Clara Ugolini Serena Battista Paola Cassoni Alessandro Gambella Francesco Cavallin Giuseppe De Lisi Alessandro Vanoli Federica Grillo Luca Mastracci Matteo Fassan
      Journal of Clinical Pathology 2023; 76 815-821 Published Online First: 13 Apr 2023. doi: 10.1136/jcp-2023-208767